VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the ...

First-in-Human Data Evaluating AMG 420 in Multiple Myeloma and AMG 330 in Acute Myeloid Leukemia Underscore Potential of BiTE ® Immunotherapy Platform Across Hematologic Malignancies BLINCYTO ® ...

Circle Pharma, a clinical-stage biopharmaceutical company advancing macrocycle therapeutics for difficult-to-treat cancers, today announced the presentation of preclinical data on CID-078 at the ...

MELBOURNE, Australia--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the presentation of data from its THRIVE-AA1 Phase 3 clinical trial during the 12 th World Congress ...

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased ...

Jade Biosciences, Inc. announced that new preclinical data on its investigational anti-APRIL monoclonal antibody, JADE101, will be presented at the 62nd European Renal Association Congress in Vienna ...

- Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to be presented in a poster session at the American Society of Clinical ...

Regeneron presents real-world data on EYLEA HD's effectiveness and economic benefits in treating retinal diseases at ARVO 2025. Regeneron Pharmaceuticals announced the upcoming presentation of data on ...

These observed declines were consistent with the inhibition of androgen receptor signaling. MDV3100 continued to be well-tolerated in all dose groups. The data were presented as part of a special late ...

GBM CTC isolation only possible with Parsortix label-free methodology Data presented at the 7 th ACTC meeting GUILDFORD, SURREY / ACCESS Newswire / September 29, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY ...